Jonathan Rigby

Mr. Jonathan Rigby has a breadth of industry knowledge and product experience, having served as President and Chief Executive Officer of Revolo Biotherapeutics, where he took the company through multiple financings and 2 phase 2 clinical trials, as well as Chairman and Chief Business Officer of BIOS Acquisition Corporation (Nasdaq: BIOS), with an oversold IPO. He served as the Chief Executive Officer of SteadyMed Therapeutics (Nasdaq: STDY), which he listed on Nasdaq prior to its acquisition by United Therapeutics (Nasdaq: UTHR), and was cofounder of Zogenix (Nasdaq: ZGNX), which was also acquired by UCB for $2 Billion after completing a Nasdaq listing.

In addition, Mr. Rigby currently serves on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. (Nasdaq: ONCY) and IM Therapeutics, which is developing therapies for T1D. He is a past board member of Thermalin Inc., which engineered new forms of insulin to improve patient lives and outcomes for the treatment of T1D, and was formerly on the board of Xeris Pharmaceuticals (Nasdaq: XERS), which developed and commercialized a therapy to treat severe hypoglycemia in patients with T1D. Mr. Rigby holds a degree in biological sciences from the University of Sheffield, UK, and has a master of business administration degree from the University of Portsmouth, UK.